

### **Genetic Technologies Announces Closing of US\$5.1 Million Registered Direct Offering**

MELBOURNE, AUSTRALIA, JULY 21 2020, Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announced the closing of its previously announced registered direct offering of 1,025,000 American Depositary Shares (“ADSs”), each representing six hundred (600) of the Company’s ordinary shares, at a purchase price of US\$5.00 per ADS or AU\$0.012 per ordinary share for gross proceeds of approximately US\$5.1 million.

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

The Company intends to use the net proceeds from this offering to support the introduction and distribution of its new products in the United States, for general product research and development and reimbursement studies for polygenic risk tests with TGen in the United States, for implementation of its consumer initiated testing platforms and preparation for its Covid-19 Severity Risk Test as well as for working capital and potential acquisitions.

Dr George Muchnicki Acting CEO and Justyn Stedwell Company Secretary On behalf of the Board of Directors  
Genetic Technologies Limited  
+61 3 9412 7000

### **About Genetic Technologies Limited**

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead products GeneType for Breast Cancer for non-hereditary breast cancer and GeneType for Colorectal Cancer are clinically validated risk assessment tests and are first in class.

Genetic Technologies has capacity for COVID-19 testing and is developing a pipeline of risk assessment products including risk of severe disease from Covid-19.

For more information, please visit [www.gtglabs.com](http://www.gtglabs.com).